Company / Interest Expense
Barinthus Biotherapeutics plc. Interest Expense History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$19.0K
FY2023
5-year range
$19.0K / $3.6M
FY2021-FY2023
Trend
-99.3%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $4M to $19,000 over the past 2 years.
Based on SEC 10-K filings.
$19,000 in FY2023.
Improved from $4M to $19,000 over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, interest expense decreased 99.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $19.0K | -99.3% |
| FY2022 | $2.7M | -25.9% |
| FY2021 | $3.6M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026